Drug Trial Radar · NCT00143507
The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction
Last checked: Nov 19, 2026Latest source record: Apr 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,917
Actual
Start
Dec 2004
Primary completion
Feb 2008
Study completion Feb 2008
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 2, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to test whether ivabradine is able to reduce cardiovascular events when given to patients with coronary artery disease and impaired heart function.
Conditions
- Coronary Disease
- Ventricular Dysfunction, Left
Interventions
IvabradineDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Composite EndpointTime frame: From the date of randomisation to the date of the first occurrence of the first event, up to 3 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Brompton National Heart and Lung Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.